Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price traded up 6.7% during mid-day trading on Tuesday . The company traded as high as $5.29 and last traded at $5.26. 7,476,874 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 16,084,284 shares. The stock had previously closed at $4.93.
Analyst Ratings Changes
A number of analysts recently commented on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $7.00.
Get Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Price Performance
The company has a market cap of $2.27 billion, a price-to-earnings ratio of -3.15 and a beta of 0.91. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The stock's 50-day simple moving average is $4.82 and its 200 day simple moving average is $6.10.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.39) earnings per share. On average, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Ensign Peak Advisors Inc increased its position in shares of Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after buying an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock valued at $176,000 after buying an additional 1,875 shares in the last quarter. Clear Creek Financial Management LLC increased its position in shares of Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock valued at $113,000 after buying an additional 1,907 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
